Abstract
Since October 3, 2001, CDC and state and local public health authorities have been investigating cases of bioterrorism-related anthrax. This report updates previous findings, provides new information on case investigations in two additional areas, presents the susceptibility patterns of Bacillus anthracis isolates, and provides interim recommendations for managing potential threats and exposures and for treating anthrax.
MeSH terms
-
Adult
-
Anthrax* / drug therapy
-
Anthrax* / epidemiology
-
Anthrax* / prevention & control
-
Anti-Bacterial Agents / therapeutic use
-
Antibiotic Prophylaxis
-
Bacillus anthracis / drug effects
-
Bacillus anthracis / genetics
-
Bacillus anthracis / isolation & purification*
-
Bioterrorism*
-
Child
-
Ciprofloxacin / therapeutic use
-
District of Columbia / epidemiology
-
Doxycycline / therapeutic use
-
Female
-
Florida / epidemiology
-
Government Agencies
-
Humans
-
Male
-
Maryland / epidemiology
-
Microbial Sensitivity Tests
-
Middle Aged
-
New Jersey / epidemiology
-
New York / epidemiology
-
Occupational Exposure / prevention & control
-
Postal Service
-
Public Health Practice*
-
Respiratory Tract Infections* / drug therapy
-
Respiratory Tract Infections* / epidemiology
-
Respiratory Tract Infections* / prevention & control
-
Skin Diseases, Bacterial* / drug therapy
-
Skin Diseases, Bacterial* / epidemiology
-
Skin Diseases, Bacterial* / prevention & control
-
Spores, Bacterial / isolation & purification*
-
United States / epidemiology
-
Virginia / epidemiology
Substances
-
Anti-Bacterial Agents
-
Ciprofloxacin
-
Doxycycline